Xspray Pharma: Shaping up to an exciting year

Research Update

2019-03-19

07:30

In this update we look at the year ahead with the manufacturing and preparations to take HyNap-Dasa to market. We also update our view regarding the Sprycel, Nexavar and Tasigna market opportunities. We see a strong case in Xspray for the year going forward and reiterate our valuation range with a Base Case of SEK 135.

JS

MS

Jakob Svensson

Mathias Spinnars

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.